SAC May Have Seen Big Profit On Drug Test News

Jan 13 2014 | 12:42pm ET

Drug trials are at the heart of the insider-trading case against a former SAC Capital Advisors trader—and have earned the hedge fund more than $200 million this year already.

SAC owned nearly 1 million shares of Intercept Pharmaceuticals at the end of September. The stock nearly tripled in value on Thursday after the company announced a positive result of a liver-disease drug.

It is unclear whether SAC still holds its Intercept shares; the firm has been returning outside capital after pleading guilty to insider-trading charges. SAC first bought Intercept shares in the second quarter, boosting its stake to more than 988,000 shares by the end of the third.

The potentially big gain would rival the amount SAC allegedly earned or saved trading on confidential tips about drug trials received by former portfolio manager Mathew Martoma. Martoma is currently on trial.


In Depth

An Interview With Harvest Volatility Management's Rick Selvala

Mar 23 2017 | 5:39pm ET

Several years of extremely low interest rates have pushed some investors into equities...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

SEI: Private Debt Coming Into Its Own

Mar 8 2017 | 9:24pm ET

The explosive growth of private debt over the past few years has caused the lines...

 

From the current issue of